StockData
Molecular Partners AG logo

Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$3.09+0.00 (0.00%)

Close on Nov 11, 2026Market cap $124.76MP/E –Yield –

Molecular Partners cash

Cash and short-term investments held at the end of each period.

Molecular Partners's cash was CHF 67.93M at Jun 30, 2026. For fiscal 2025 it was CHF 82.65M, up 29.4% from the year before. The highest annual figure on record is CHF 133.72M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 82.65M+29.4%
FY2024Dec 31, 2024CHF 63.87M-5.1%
FY2023Dec 31, 2023CHF 67.31M-23.5%
FY2022Dec 31, 2022CHF 87.95M+22.5%
FY2021Dec 31, 2021CHF 71.81M-46.3%
FY2020Dec 31, 2020CHF 133.72M+76.6%
FY2019Dec 31, 2019CHF 75.71M-23.5%
FY2018Dec 31, 2018CHF 98.96M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026CHF 67.93M+6.0%
Q4 FY2025Dec 31, 2025CHF 82.65M+22.8%
Q2 FY2025Jun 30, 2025CHF 81.98M+29.6%
Q4 FY2024Dec 31, 2024CHF 63.87M-27.4%
Q2 FY2024Jun 30, 2024CHF 64.06M-44.3%
Q4 FY2023Dec 31, 2023CHF 67.31M-6.3%
Q2 FY2023Jun 30, 2023CHF 63.24M-50.0%
Q4 FY2022Dec 31, 2022CHF 87.95M-34.2%
Q2 FY2022Jun 30, 2022CHF 114.94M+51.8%
Q4 FY2021Dec 31, 2021CHF 71.81M-27.4%
Q2 FY2021Jun 30, 2021CHF 126.57M–
Q4 FY2020Dec 31, 2020CHF 133.72M–
Q4 FY2019Dec 31, 2019CHF 75.71M–
Q4 FY2018Dec 31, 2018CHF 98.96M–

More Molecular Partners figures

See a number that looks wrong?